|
Hikma Pharmaceuticals PLC is a global pharmaceutical company that develops, manufactures, and supplies generic, specialty, and branded medicines. The company operates through three main business segments: Injectables, which provides generic and specialty injectable medicines to hospitals in North America, Europe, and the Middle East and North Africa (MENA); Branded, which supplies branded generics and licensed products across the MENA region; and Hikma Rx, which offers oral, nasal, respiratory, and specialty medicines in North America. Founded in 1978 in Jordan, the company has expanded its presence through acquisitions, including West-Ward Pharmaceuticals, Ribosepharm GmbH, Thymoorgan, Alkan Pharma, Arab Pharmaceutical Manufacturing Company (APM), Teligent Inc., Custopharm Inc., and Xellia’s US finished dosage form business. Its manufacturing network spans facilities in the United States, Europe, and MENA, with R&D hubs in Columbus, Ohio; Amman, Jordan; and Zagreb, Croatia. Hikma serves patients and healthcare providers across North America, Europe, and the MENA region, focusing on therapeutic areas such as respiratory, oncology, and pain management. Summarised from the company's own disclosures, fiscal year ended Dec 2025 |
Industry Drug Manufacturers - General | Homepage hikma.com |
| Sector Healthcare | IR page hikma.com/investors | |
|
Tags
generic medicines, specialty medicines, branded generics, injectables, oral solids, respiratory, oncology, pain management, cephalosporins, contract manufacturing, Hikma Rx, West-Ward Pharmaceuticals, Ribosepharm GmbH, Thymoorgan, Alkan Pharma, Arab Pharmaceutical Manufacturing Company, APM, Al Dar Al Arabia, Baxter’s multi-source injectables business, Bedford Laboratories, Ben Venue Laboratories Inc, Société de Promotion Pharmaceutique du Maghreb S.A., Roxane Laboratories, Teligent Inc., Custopharm Inc., Xellia
|
Press page hikma.com/news |
Metrics
| Valuation | |
|---|---|
| Market cap | £ 3.645B |
| Market cap (USD) | $ 4.892B |
| P/E | 12.13 |
| PEG | 0.42 |
| P/BV | 1.87 |
| P/S | 1.46 |
| P/OCF | 11.19 |
| P/FCF | — |
| Dividend yield | — |
| Turnover / mcap | — |
| Returns | |
|---|---|
| ROE | 16.5% |
| ROI | 10.0% |
| ROIC | 10.5% |
| Profit margin | 12.2% |
| Growth | |
|---|---|
| Revenue growing | Yes |
| Profits growing | Yes |
| Revenue up 3y | Yes |
| Revenue up 5y | No |
| Earnings growth 3y (net profit CAGR) | 28.8% |
| Quality | |
|---|---|
| Profitable | Yes |
| Margin expanding | No |
| Buying back stock | No |
| Diluting (TTM) | Yes |
| Debt/Equity | 55.4% |
| Podcast bulls (TTM) | Sign up |
| Podcast bears (TTM) | Sign up |
| Podcast sentiment (TTM) | Sign up |
| Podcast sentiment % (TTM) | Sign up |
| News sentiment (TTM) | 22 |
| Quality score | 29.4% |
| Insiders | |
|---|---|
| Buys, 1w | Sign up |
| Buys, 1m | Sign up |
| Buys, 1y | Sign up |
| Sells, 1w | Sign up |
| Sells, 1m | Sign up |
| Sells, 1y | Sign up |
Sign up to see this company's insider trades
| Figure | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 | FY 2011 | FY 2010 | FY 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.349B | 3.127B | 2.875B | 2.517B | 2.553B | 2.341B | 2.203B | 2.07B | 1.936B | 1.95B | 1.44B | 1.489B | 1.365B | 1.109B | 918.025M | 730.936M | 636.884M |
| Net profit | 407M | 362M | 192M | 191M | 420M | 430M | 365M | 285M | 256M | 279M | 288M | 282M | 216M | 107.215M | 83.469M | 99.527M | 79.318M |
Filed figures
Lines the statements and their notes report beside the headline figures, read from the filings' XBRL as filed (no restatement applied), with figures computed from one filing's own lines. Cash-flow lines carry their cash direction: an outflow is negative. Each period links to its filing; a figure's period, report date and tag are in its tooltip.
| Figure | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Balance sheet detail | |||||||
| Trade receivables (USD) | — | 700M | 816M | 809M | 824M | 949M | 1.06B |
| ↳ YoY growth | +16.6% | -0.9% | +1.9% | +15.2% | +11.8% | ||
| ↳ 5y CAGR | +8.7% | ||||||
| Borrowings, current (USD) | — | 158M | 112M | 139M | 150M | 642M | 106M |
| Borrowings, non-current (USD) | — | 692M | 651M | 1.07B | 975M | 607M | 1.45B |
| Lease liabilities (USD) | — | 82M | 83M | 70M | 66M | 57M | 53M |
| Cash and deposits (USD) | 442M | 323M | 426M | 270M | 205M | 188M | 217M |
| Intangible assets (USD) | — | 587M | 607M | 735M | 712M | 774M | 777M |
| Right-of-use assets (USD) | — | 59M | 74M | 57M | 45M | 48M | 44M |
| Net debt (borrowings + leases - cash) (USD) | — | 609M | 420M | 1.01B | 986M | 1.12B | 1.39B |
| Cash flow detail | |||||||
| Operating cash flow (USD) | — | 464M | 638M | 530M | 608M | 564M | 436M |
| Purchases of property, plant and equipment (USD) | — | -172M | -145M | -138M | -169M | -165M | -197M |
| Purchases of intangible assets (USD) | — | -52M | -84M | -87M | -35M | -70M | -120M |
| Change in receivables (cash effect) (USD) | — | — | — | — | — | -144M | -97M |
| Change in inventories (cash effect) (USD) | — | — | — | — | — | -112M | -86M |
| Change in payables (cash effect) (USD) | — | — | — | — | — | 78M | 38M |
| Dividends paid (cash effect) (USD) | — | -109M | -120M | -125M | -137M | -175M | -185M |
| Share buybacks (cash effect) (USD) | — | -375M | 0.00 | -300M | 0.00 | -38M | -36M |
| Income taxes paid (cash effect) (USD) | — | -68M | -131M | -103M | -131M | -125M | -126M |
| Operating cash flow before change in receivables (USD) | — | — | — | — | — | 708M | 533M |
| Free cash flow (OCF - PPE - intangibles) (USD) | — | 240M | 409M | 305M | 404M | 329M | 119M |
| Income detail | |||||||
| Research and development expense (USD) | — | 137M | 143M | 144M | 149M | 141M | 151M |
| ↳ 5y CAGR | +2.0% | ||||||
| Total comprehensive income (USD) | — | 470M | 411M | 88M | 177M | 300M | 486M |
| Comprehensive income to owners (USD) | — | 468M | 409M | 88M | 175M | 297M | 481M |
| Reported | Mar 17, 2022 | Mar 17, 2022 | Mar 17, 2022 | Mar 16, 2023 | Mar 22, 2024 | Mar 18, 2026 | Mar 18, 2026 |
Sign up to see institutional holdings
Sign UpPodcast Mentions
Sign up to see podcast mentions and sentiment
Sign UpResults, director/PDMR dealings and voting-rights totals announced to the FCA's National Storage Mechanism, newest first. The link opens the announcement on the NSM. Press releases from the company's own website, newest first.
Press Release Product 15 October 2026
Hikma launches Fidaxomicin Tablets in the US
London, UK, 15 October 2026 – Hikma Pharmaceuticals PLC (Hikma, Group), a multinational pharmaceutical company, today announced the US launch of Fidaxomicin Tablets in 200mg, expanding its US portfolio.
The product is indicated in adults for the treatment of Clostridioides difficile-associated diarrhea (CDAD). Please see below for Important Safety Information and refer to the full Prescribing Information at https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d773c5ee-9361-49b0-871b-af34f3f936be
"C. difficile infection is a serious and often recurring condition, and hospitals, clinicians and patients need dependable access to effective treatment options," said Hafrun Fridriksdottir, US President and Chief R&D Officer at Hikma. "Fidaxomicin is an important addition to our portfolio, and it helps broaden access to this medicine for patients across the US. We are manufacturing Fidaxomicin Tablets in the US, at our state-of-the-art facility in Columbus, Ohio, furthering Hikma’s position as one of the nation’s largest domestic producers of high-quality essential generic medicines."
According to IQVIA, US sales of Fidaxomicin Tablets were approximately $360 million in the 12 months ending June 2026.
Hikma supplies a broad range of increasingly complex non-injectable products to the US market. Our Columbus, Ohio facility supports this portfolio, and we are committed to continued investment in US manufacturing.
– ENDS –
This product has been approved for marketing in the United States by the US FDA. This product approval does not confer the right on Hikma, or any other party, to market this product outside the United States.
About Hikma
Hikma helps put better health within reach every day for millions of people around the world. For more than 45 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we are a global company with a local presence across North America, the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 9,400 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit: www.hikma.com
Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (LEI:549300BNS685UXH4JI75) (rated BBB/stable S&P and BBB/stable Fitch)
HK-3671
Enquiries
Hikma Pharmaceuticals PLC
Susan Ringdal
EVP, Strategic Planning and Global Affairs
+44 (0)20 7399 2760/ +44 7776 477050
Steven Weiss
US Communications
+1 732 788 8279
IMPORTANT SAFETY INFORMATION FOR FIDAXOMICIN TABLETS
CONTRAINDICATIONS
Fidaxomicin is contraindicated in patients who have known hypersensitivity to fidaxomicin or any other ingredient in fidaxomicin tablets.
WARNINGS AND PRECAUTIONS
-
**Hypersensitivity Reactions
**Acute hypersensitivity reactions, including dyspnea, rash, pruritus, and angioedema of the mouth, throat, and face have been reported with fidaxomicin. If a severe hypersensitivity reaction occurs, fidaxomicin should be discontinued and appropriate therapy instituted.
Some patients with hypersensitivity reactions to fidaxomicin also reported a history of allergy to other macrolides. Physicians prescribing fidaxomicin to patients with a known macrolide allergy should be aware of the possibility of hypersensitivity reactions.
-
**Not for Use in Infections Other than Clostridioides difficile-Associated Diarrhea (CDAD)
**Fidaxomicin is not expected to be effective for the treatment of other types of infections. Fidaxomicin should only be used for the treatment of CDAD.
-
**Development of Drug-Resistant Bacteria
**Prescribing fidaxomicin in the absence of proven or strongly suspected C. difficile infection is unlikely to benefit the patient and increases the risk of the development of drug-resistant bacteria.
ADVERSE REACTIONS
Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Adults
The safety of fidaxomicin 200 mg tablets taken twice daily for 10 days was evaluated in 564 adult patients with CDAD in two active-controlled trials with 86.7% of patients receiving a full course of treatment.
Thirty-three (33) adult patients receiving fidaxomicin (5.9%) withdrew from trials as a result of adverse reactions. The following adverse reactions were reported in ≥2% of adult patients taking fidaxomicin tablets in controlled trials:
Gastrointestinal Disorders: nausea, vomiting, abdominal pain, gastrointestinal hemorrhage
Blood and Lymphatic System Disorders: anemia, neutropenia
The following adverse reactions were reported in <2% of adult patients taking fidaxomicin tablets in controlled trials:
Gastrointestinal Disorders: abdominal distension, abdominal tenderness, dyspepsia, dysphagia, flatulence, intestinal obstruction, megacolon
Investigations: increased blood alkaline phosphatase, decreased blood bicarbonate, increased hepatic enzymes, decreased platelet count
Metabolism and Nutrition Disorders: hyperglycemia, metabolic acidosis
Skin and Subcutaneous Tissue Disorders: drug eruption, pruritus, rash
See the Full Prescribing Information for fidaxomicin tablets for more information about these trials.
Post Marketing Experience
The following adverse reactions have been identified during post-approval use of fidaxomicin. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Hypersensitivity reactions (dyspnea, angioedema, rash, pruritus)
Pediatric use information is approved for Cubist Pharmaceuticals LLC’s DIFICID® (fidaxomicin) tablets. However, due to Cubist Pharmaceuticals LLC’s marketing exclusivity rights, this drug product is not labeled with that information.
DRUG INTERACTIONS
Fidaxomicin and its main metabolite, OP-1118, are substrates of P-glycoprotein (P-gp), which is expressed in the gastrointestinal tract.
- **Cyclosporine
**
Cyclosporine is an inhibitor of multiple transporters, including P-gp. When cyclosporine was co-administered with fidaxomicin, plasma concentrations of fidaxomicin and OP-1118 were significantly increased but remained in the ng/mL range. Concentrations of fidaxomicin and OP-1118 may also be decreased at the site of action (i.e., gastrointestinal tract) via P-gp inhibition; however, concomitant P-gp inhibitor use had no attributable effect on safety or treatment outcome of fidaxomicin-treated adult patients in controlled clinical trials. Based on these results, fidaxomicin may be co-administered with P-gp inhibitors and no dose adjustment is recommended.
USE IN SPECIFIC POPULATIONS
-
**Pregnancy
**The limited available data on use of fidaxomicin in pregnant women are insufficient to inform any drug-associated risk for major birth defects, miscarriage, or adverse maternal or fetal outcomes.
-
**Lactation
**There is no information on the presence of fidaxomicin or its main metabolite, OP-1118, in human milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for fidaxomicin and any potential adverse effects on the breastfed infant from fidaxomicin or from the underlying maternal condition.
-
**Pediatric Use
**The safety and effectiveness of fidaxomicin in pediatric patients have not been established in patients younger than 6 months of age.
_Pediatric use information is approved for Cubist Pharmaceuticals LLC’s DIFICID® (fidaxomicin) tablets. However, due to Cubist Pharmaceuticals LLC’s marketing exclusivity rights, this drug product is not labeled with that information.
_
-
**Geriatric Use
**No overall differences in safety or effectiveness of fidaxomicin compared to vancomycin were observed between younger patients and those 65 years of age and older.
PATIENT COUNSELING INFORMATION
When fidaxomicin tablets are prescribed to treat a C. difficile infection, patients should be told that, although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by fidaxomicin tablets or other antibacterial drugs in the future.
Press Release Product 14 October 2026
Hikma launches Deflazacort Tablets in the US
London, UK, 14 October 2026 – Hikma Pharmaceuticals PLC (Hikma, Group), a multinational pharmaceutical company, today announced the US launch of Deflazacort Tablets in four strengths (6mg, 18mg, 30mg, and 36mg), expanding its rare disease portfolio.
The product is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 2 years of age and older. Please see Important Safety Information below and full Prescribing Information at https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=00df3169-b8e3-4584-823b-91b71807d1a6
“Duchenne muscular dystrophy is a rare, progressive condition, and the families managing it depend on uninterrupted access to standard-of-care medicines,” said Hafrun Fridriksdottir, US President and Chief R&D Officer at Hikma. “This is our latest rare disease launch and reflects our ongoing focus on more complex products where reliable supply matters most. We are manufacturing Deflazacort Tablets in the US, at our state-of-the-art facility in Columbus, Ohio, and adding a further qualified, domestic supplier to this market helps support continuity for patients and their caregivers.”
According to IQVIA, US sales of Deflazacort Tablets were approximately $25 million in the 12 months ending June 2026.
Hikma supplies a broad range of increasingly complex non-injectable products to the US market. Our Columbus, Ohio facility supports this portfolio, and we are committed to continued investment in US manufacturing.
– ENDS –
This product has been approved for marketing in the United States by the US FDA. This product approval does not confer the right on Hikma, or any other party, to market this product outside the United States.
About Hikma
Hikma helps put better health within reach every day for millions of people around the world. For more than 45 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we are a global company with a local presence across North America, the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 9,400 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit: www.hikma.com
Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (LEI:549300BNS685UXH4JI75) (rated BBB/stable S&P and BBB/stable Fitch)
Enquiries
Hikma Pharmaceuticals PLC
Susan Ringdal
EVP, Strategic Planning and Global Affairs
+44 (0)20 7399 2760/ +44 7776 477050
Steven Weiss
US Communications
+1 732 788 8279
IMPORTANT SAFETY INFORMATION AND INDICATIONS FOR DEFLAZACORT TABLETS
INDICATIONS
Deflazacort tablets are indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 2 years of age and older.
CONTRAINDICATIONS
Deflazacort tablets are contraindicated in patients with known hypersensitivity to deflazacort or to any of the inactive ingredients.
WARNINGS AND PRECAUTIONS
- Alterations in Endocrine Function—Corticosteroids, such as deflazacort tablets, can cause serious and life-threatening alterations in endocrine function, especially with chronic use. Monitor patients for Cushing’s syndrome, hyperglycemia and adrenal insufficiency after deflazacort tablets withdrawal. In addition, patients with hypopituitarism, primary adrenal insufficiency or congenital adrenal hyperplasia, altered thyroid function or pheochromocytoma may be at increased risk for adverse endocrine events. Corticosteroids produce reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, with the potential for the development of secondary adrenal insufficiency after withdrawal of corticosteroid treatment. Acute adrenal insufficiency can occur if corticosteroids are withdrawn abruptly, and can be fatal. The degree and duration of adrenocortical insufficiency produced varies and depends on the dose, frequency and duration of corticosteroid therapy. The risk is reduced by gradually tapering the corticosteroid dose when withdrawing treatment. This insufficiency may persist, however, for months after discontinuation of prolonged therapy; therefore, in any situation of stress occurring during that period of discontinuation, corticosteroid therapy should be reinstituted. For patients already taking corticosteroids during times of stress, the dosage may need to be increased. A steroid “withdrawal syndrome,” seemingly unrelated to adrenocortical insufficiency, may also occur following abrupt discontinuance of corticosteroids. Corticosteroids can increase blood glucose, worsen pre-existing diabetes, predispose those on long-term therapy to diabetes mellitus and may reduce the effect of anti-diabetic drugs. Metabolic clearance of corticosteroids is decreased in hypothyroid patients and increased in hyperthyroid patients. Changes in thyroid status of the patient may necessitate a dose adjustment of the corticosteroid. When concomitant administration of corticosteroids and levothyroxine is required, administration of corticosteroid should precede the initiation of levothyroxine therapy to reduce the risk of adrenal crisis. There have been reports of pheochromocytoma crisis, which can be fatal, after administration of systemic corticosteroids. In patients with suspected or identified pheochromocytoma, consider the risk of pheochromocytoma prior to administering corticosteroids.
- Immunosuppression and Increased Risk of Infection—Corticosteroids can reduce resistance to new infections, exacerbate existing infections, increase the risk of disseminated infections, increase the risk of reactivation or exacerbation of latent infections or mask some signs of infection. Corticosteroid-associated infections can be mild but can be severe, and at times fatal. The rate of infectious complications increases with increasing corticosteroid dosages. Monitor for the development of infection and consider deflazacort tablets withdrawal or dosage reduction as needed. If deflazacort tablets are used to treat a condition in patients with latent tuberculosis or tuberculin reactivity, reactivation of tuberculosis may occur. Closely monitor such patients for reactivation. During prolonged deflazacort tablets therapy, patients with latent tuberculosis or tuberculin reactivity should receive chemoprophylaxis. Varicella and measles can have a serious or even fatal course in non-immune patients taking corticosteroids, including deflazacort tablets; particular care should be taken to avoid exposure to varicella and measles. Hepatitis B virus reactivation can occur in patients who are hepatitis B carriers treated with immunosuppressive dosages of corticosteroids, including deflazacort tablets. Reactivation can also occur infrequently in corticosteroid-treated patients who appear to have resolved hepatitis B infection. Screen patients for hepatitis B infection before initiating immunosuppressive treatment with deflazacort tablets. Corticosteroids, including deflazacort tablets, may exacerbate systemic fungal infections; therefore, avoid deflazacort tablets use in the presence of such infections unless deflazacort tablets is needed to control drug reactions. For patients on deflazacort tablets who develop systemic fungal infections, deflazacort tablets withdrawal or dose reduction is recommended. Corticosteroids, including deflazacort tablets, may activate latent amebiasis. Therefore, it is recommended that latent amebiasis or active amebiasis be ruled out before initiating deflazacort tablets in patients who have spent time in the tropics or patients with unexplained diarrhea. Corticosteroids, including deflazacort tablets, should be used with great care in patients with known or suspected Strongyloides (threadworm) infestation. Corticosteroid-induced immunosuppression may lead to Strongyloides hyperinfection and dissemination with widespread larval migration, often accompanied by severe enterocolitis and potentially fatal gram-negative septicemia. Avoid corticosteroids, including deflazacort tablets, in patients with cerebral malaria.
- Alteration in Cardiovascular/Renal Function—Monitor blood pressure and assess for signs and symptoms of volume overload. Monitor serum potassium levels. Dietary salt restriction and potassium supplementation may be necessary. Use deflazacort tablets with caution in patients with congestive heart failure, hypertension or renal insufficiency. Literature reports suggest an association between corticosteroid use and left ventricular free wall rupture after a recent myocardial infarction; therefore, deflazacort tablets should be used with great caution in these patients.
- Gastrointestinal Perforation—There is an increased risk of gastrointestinal perforation during corticosteroid use in patients with certain gastrointestinal disorders such as active or latent peptic ulcers, diverticulitis, fresh intestinal anastomoses and non-specific ulcerative colitis. Signs of gastrointestinal perforation may be masked. Avoid corticosteroids if there is a probability of impending perforation, abscess or other pyogenic infections; diverticulitis; fresh intestinal anastomoses or active or latent peptic ulcer.
- Behavioral or Mood Disturbances—Potentially severe psychiatric adverse reactions may occur with systemic corticosteroids, including deflazacort tablets. Symptoms typically emerge within a few days or weeks of starting treatment and may be dose-related. Psychiatric reactions usually involve hypomanic or manic symptoms during treatment and depressive episodes after discontinuation of treatment. Inform patients or caregivers and encourage them to seek medical attention if psychiatric symptoms develop, especially if depressed mood or suicidal ideation is suspected.
- Effects on Bones—Corticosteroids, including deflazacort tablets, have the potential to cause inhibition of bone growth in pediatric patients and the development of bone loss at any age. Bone loss can predispose patients to vertebral and long bone fractures. Consider a patient’s risk of osteoporosis before initiating corticosteroid therapy. Monitor bone mineral density in patients on long-term treatment with deflazacort tablets. Corticosteroids, including deflazacort tablets, may cause avascular necrosis.
- Ophthalmic Effects—Corticosteroids, including deflazacort tablets, may produce posterior subcapsular cataracts. Corticosteroids may also cause glaucoma with possible damage to the optic nerves, and may increase the risk of secondary ocular infections caused by bacteria, fungi or viruses. Corticosteroids are not recommended for patients with active ocular herpes simplex. Monitor intraocular pressure if treatment with deflazacort tablets is continued for more than 6 weeks.
- Immunizations—Administer all immunizations according to immunization guidelines prior to starting deflazacort tablets. Administer live-attenuated or live vaccines at least 4 to 6 weeks prior to starting deflazacort tablets. Patients on deflazacort tablets may receive concurrent vaccinations, except for live-attenuated or live vaccines.
- Serious Skin Rashes—Toxic epidermal necrolysis has been reported with the use of deflazacort. Discontinue at the first sign of rash, unless the rash is clearly not drug-related.
- Effects on Growth and Development—Long-term use of corticosteroids, including deflazacort tablets, can have negative effects on growth and development in children.
- Myopathy—Patients receiving corticosteroids, including deflazacort tablets, and concomitant therapy with neuromuscular blocking agents or patients with disorders of neuromuscular transmission may be at increased risk of developing acute myopathy.
- Kaposi’s Sarcoma—Kaposi’s sarcoma has been reported to occur in patients receiving corticosteroid therapy, most often for chronic conditions.
- Thromboembolic Events—Observational studies have shown an increased risk of thromboembolism particularly with higher cumulative doses of corticosteroids. Use deflazacort tablets with caution in patients who have or may be predisposed to thromboembolic disorders.
- Anaphylaxis—Rare instances of anaphylaxis have occurred in patients receiving corticosteroid therapy, including deflazacort tablets.
ADVERSE REACTIONS
Serious adverse reactions are described in the Warnings and Precautions section, above, and in the Full Prescribing Information for deflazacort tablets.
Clinical Trials Experience
Adverse reactions occurring in >5% of DMD patients treated with deflazacort 0.9 mg/kg/day at 12 weeks included Cushingoid appearance, weight increased, increased appetite, upper respiratory tract infection, cough, pollakiuria, nasopharyngitis, hirsutism, central obesity, erythema, irritability, rhinorrhea and abdominal discomfort.
DRUG INTERACTIONS
Give one-third the recommended dosage of deflazacort tablets when moderate or strong CYP3A4 inhibitors (e.g., clarithromycin, fluconazole, diltiazem, verapamil, grapefruit juice) are used concomitantly with deflazacort tablets. Avoid concomitant use of strong or moderate CYP3A4 inducers with deflazacort tablets, as they may reduce efficacy. Patients receiving corticosteroids, including deflazacort tablets, and concomitant therapy with neuromuscular blocking drugs may be at increased risk of developing an acute myopathy.
USE IN SPECIFIC POPULATIONS
- Pregnancy—Corticosteroids should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Infants born to mothers who have received substantial doses of corticosteroids during pregnancy should be carefully observed for signs of hypoadrenalism. Corticosteroids, including deflazacort tablets, readily cross the placenta.
- Lactation—Systemically administered corticosteroids appear in human milk and could suppress growth, interfere with endogenous corticosteroid production or cause other untoward effects. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for deflazacort tablets and any potential adverse effects on the breastfed infant.
- Pediatric Use—Safety and effectiveness in pediatric patients below the age of 2 years have not been established.
- Hepatic Impairment—There is no clinical experience in patients with severe hepatic impairment and a dosing recommendation cannot be provided for these patients.
Prompts
Click prompts to add them under the company line, click again to take one out, then copy the result into your AI chat. Shared by Asian Century Stocks and Uncovered Thai Stocks. Thank you.
ETFs Holding Hikma Pharmaceuticals PLC
Exchange-traded funds whose newest published daily portfolio holds one of the company's listings, largest weight first.
| ETF | Weight in ETF | Shares | Market value | As of |
|---|---|---|---|---|
| COPY | 0.57% | 110,094 | $ 2.411M | Aug 31, 2026 |
| EMSF | 0.22% | 5,347 | $ 107.872K | Jun 30, 2026 |
| DISV | 0.18% | 410,140 | $ 8.958M | Nov 12, 2026 |
| GMOI | 0.15% | 47,218 | $ 1.034M | Aug 31, 2026 |
| AVDS | 0.13% | 21,336 | $ 469.184K | Nov 16, 2026 |
| DFIS | 0.09% | 241,631 | $ 5.278M | Nov 12, 2026 |
| DFIC | 0.04% | 265,935 | $ 5.809M | Nov 12, 2026 |
| DXIV | 0.03% | 3,781 | $ 82.584K | Nov 12, 2026 |
| AVDE | 0.03% | 261,221 | $ 5.744M | Nov 16, 2026 |
| DFAX | 0.02% | 111,388 | $ 2.433M | Nov 12, 2026 |
| DFSI | 0.02% | 9,153 | $ 199.919K | Nov 12, 2026 |
| DFAI | 0.01% | 123,938 | $ 2.707M | Nov 12, 2026 |
| AVSD | 0.01% | 1,438 | $ 31.622K | Nov 16, 2026 |



